# AI-Accelerated Drug Discovery Pipeline

## Overview
This document outlines an advanced, AI-driven workflow for modern drug discovery. It integrates multi-omics data, generative AI, and automated feedback loops to accelerate the journey from target identification to clinical trials.

The pipeline is designed to leverage recent breakthroughs in:
- **Generative AI** (Diffusion models, LLMs) for molecule design and target identification.
- **Structural Biology** (AlphaFold 3, ESMFold) for structure-based drug design.
- **Multi-omics Integration** for holistic disease understanding.

---

## 1. Target Identification & Prioritization
**Goal:** Identify and validate biological targets (proteins, genes, RNAs) that play a key role in the disease pathology and are modulated by therapeutic intervention.

### Workflow Steps
1.  **Multi-Omics Data Ingestion**: Aggregation of Genomics, Transcriptomics, Proteomics, etc.
2.  **AI/ML Evidence Engine**:
    -   **Knowledge Graphs (KG)**: Integrate heterogeneous data (Open Targets, literature, pathways) to find non-obvious associations.
    -   **NLP/LLMs**: Extract relationships from scientific literature (PubMed, patents).
    -   **Causal Inference**: Distinguish correlation from causation using Mendelian Randomization or causal network learning.
3.  **Target Scoring & Ranking**: Rank targets based on druggability, safety, genetic evidence, and novelty.
4.  **Experimental Target Validation (Wet Lab)**: **[CRITICAL STEP]** CRISPR/Cas9 knockouts, RNAi, or chemical probes to validate biological relevance in disease models before proceeding.

### User Story
-   **User**: Computational Biologist / Discovery Scientist.
-   **Action**: Selects disease indication (e.g., via MONDO ontology).
-   **System**: Aggregates evidence from curated databases and dynamic literature analysis. Generates an "Evidence Heatmap" highlighting strong targets.
-   **Review**: User reviews target rationale (e.g., "Genetic evidence from GWAS", "Up-regulated in patient tissue").
-   **Structure**: System retrieves experimental structures (PDB) or predicts them (AlphaFold 3/ESMFold) and identifies binding pockets (CrypticSite prediction).
-   **Decision**: User confirms target and initiates the validation plan.

### Technologies
-   **Databases**: Open Targets, GWAS Catalog, gnomAD, STRING.
-   **AI Models**: Graph Neural Networks (GNNs) for link prediction; BERT/GPT-based NER for literature mining.
-   **Tools**: PyG (PyTorch Geometric), BioBERT, AlphaFold 3.

---

## 2. Hit Identification & Lead Generation
**Goal:** Identify small molecules (hits) that bind to the target and modulate its activity, then refine them into leads.

### Workflow Steps
1.  **Virtual Screening**: Screening billion-scale libraries (ZINC20, Enamine REAL).
2.  **De Novo Generative Design**: Creating novel chemical structures using AI.
3.  **Binding Affinity Prediction**: Predicting interaction strength.
4.  **Hit Selection & Purchase/Synthesis**: Selecting top candidates for testing.
5.  **Experimental Screening (HTS/DEL)**: High-throughput screening or DNA-encoded library screening.

### User Story
-   **User**: Medicinal Chemist.
-   **Action**: Defines target pocket and desired properties (e.g., scaffold preferences).
-   **System**:
    -   Runs **Virtual Screening** using structure-based (docking) or ligand-based (similarity) methods.
    -   Uses **Generative Models** (Diffusion models, REINVENT) to propose novel binders.
    -   Predicts poses (DiffDock) and affinity (DeepAffinity, GNINA).
-   **Review**: User filters hits by synthetic accessibility (SAScore) and IP novelty.
-   **Confirmation**: Top hits are ordered/synthesized and tested in biochemical assays. Validated hits become "Leads".

### Technologies
-   **Virtual Screening**: AutoDock Vina, GNINA (Deep Learning docking), Uni-Mol.
-   **Generative AI**: REINVENT (RNN/Transformer), MolGPT, DiffDock (Diffusion for docking), RFdiffusion (for protein binders).
-   **Libraries**: ZINC, Enamine REAL Space.

---

## 3. Lead Optimization
**Goal:** Optimize lead compounds for potency, selectivity, and drug-like properties (ADME/Tox).

### Workflow Steps
1.  **Multi-Parameter Optimization (MPO)**: Balancing potency, solubility, permeability, and metabolic stability.
2.  **FEP/Binding Free Energy**: High-accuracy physics-based simulations to predict potency changes.
3.  **ADME/Tox Prediction**: Early identification of safety risks (hERG inhibition, CYP induction).
4.  **Design-Make-Test-Analyze (DMTA) Cycle**: Iterative loops of improvement.

### User Story
-   **User**: Lead Chemist / DMPK Scientist.
-   **Action**: Submits lead series for optimization.
-   **System**:
    -   **QSAR/QSPR Models**: Predict logP, solubility, clearance.
    -   **Tox Models**: Predict AMES toxicity, hERG blockage (DeepTox).
    -   **FEP+**: Calculates relative binding free energies for proposed modifications.
-   **Refinement**: User selects analogs with the best "MPO Score".
-   **Outcome**: Identification of a **Preclinical Candidate (PCC)** that meets the Target Product Profile (TPP).

### Technologies
-   **ADME/Tox**: SwissADME, ADMETlab 2.0, pkCSM, TDC (Therapeutics Data Commons) models.
-   **Dynamics**: GROMACS, OpenMM (for MD simulations), FEP (Free Energy Perturbation).
-   **Cheminformatics**: RDKit, DeepChem.

---

## 4. Preclinical In Vivo Studies
**Goal:** Demonstrate efficacy and safety in animal models to support regulatory filing (IND).

### Workflow Steps
1.  **In Vivo Efficacy**: Testing in disease-relevant animal models.
2.  **PK/PD Modeling**: Establishing the relationship between drug exposure (Pharmacokinetics) and effect (Pharmacodynamics).
3.  **GLP Toxicology**: Rigorous safety testing required by regulators.
4.  **Biomarker Discovery**: Identifying markers to monitor patient response in clinics.

### User Story
-   **User**: Translational Scientist.
-   **Action**: Designs in vivo study protocols.
-   **System**:
    -   Analyzes PK data to predict human dosage (Allometric scaling).
    -   Correlates animal efficacy with human biomarker data.
-   **Decision**: "Go/No-Go" decision for IND-enabling studies.

---

## 5. Clinical Trials (Phases I-III)
**Goal:** Prove safety and efficacy in humans.

### Workflow Steps
1.  **Phase I**: Safety, tolerability, and PK in healthy volunteers.
2.  **Phase II**: Proof of concept (efficacy) and dose-ranging in patients.
3.  **Phase III**: Large-scale confirmatory trials.
4.  **Regulatory Submission**: NDA/BLA filing.

### Technologies
-   **Trial Design**: AI for patient stratification and synthetic control arms.
-   **Digital Biomarkers**: Wearables and remote monitoring.

---

## Omics & Databases Reference

A comprehensive list of open-source databases and resources used in the pipeline.

### 1. Genomics
*Study of the genome (DNA sequence, variants, and gene annotation).*
-   **ENA / GenBank**: Comprehensive nucleotide sequence archives.
-   **Ensembl / RefSeq**: Genome annotation and reference sequences.
-   **gnomAD**: Genome Aggregation Database (population variation).
-   **ClinVar**: Relationships between genetic variations and clinical phenotypes.
-   **GWAS Catalog**: Genome-Wide Association Studies results.
-   **GTEx**: Genotype-Tissue Expression (gene regulation in tissues).

### 2. Transcriptomics
*Study of the transcriptome (RNA expression and splicing profiles).*
-   **GEO / ArrayExpress**: Repositories for functional genomics data.
-   **Expression Atlas**: Gene expression across species and conditions.
-   **Human Cell Atlas (HCA)**: Single-cell maps of human tissues.
-   **cellxgene**: Interactive explorer for single-cell transcriptomics.
-   **Tabula Sapiens**: Multi-organ single-cell transcriptomic atlas.

### 3. Proteomics
*Study of the proteome (Protein abundance, modifications, and structures).*
-   **UniProt**: Central hub for protein sequence and functional information.
-   **PRIDE**: Proteomics identifications database (mass spectrometry).
-   **ProteomicsDB**: Human proteome archive.
-   **PeptideAtlas**: Compendium of peptides identified by mass spec.
-   **AlphaFold DB**: Predicted structures for nearly all known proteins.

### 4. Metabolomics
*Study of the metabolome (Small-molecule metabolites and pathways).*
-   **HMDB**: Human Metabolome Database.
-   **MetaboLights**: Repository for metabolomics experiments.
-   **GNPS**: Global Natural Products Social Molecular Networking.
-   **MassBank**: High-resolution mass spectral database.

### 5. Epigenomics
*Study of epigenetic modifications (Chromatin marks regulating gene expression).*
-   **ENCODE**: Encyclopedia of DNA Elements.
-   **Roadmap Epigenomics**: Human epigenomic data.
-   **Cistrome**: ChIP-seq and chromatin accessibility data.

### 6. Interactomics
*Study of molecular interaction networks.*
-   **Reactome**: Curated biological pathways.
-   **STRING**: Protein-protein interaction networks (functional and physical).
-   **BioGRID**: Biological General Repository for Interaction Datasets.
-   **IntAct**: Molecular interaction database.

### 7. Phenomics
*Study of phenotypes and genotype-phenotype links.*
-   **HPO**: Human Phenotype Ontology.
-   **OMIM**: Online Mendelian Inheritance in Man.
-   **Monarch Initiative**: Integrative data on genotypes and phenotypes.
-   **UK Biobank**: Large-scale biomedical database with genetic and health data.

### 8. Cheminformatics & Structural Biology
*Chemical properties, structures, and bioactivity data.*
-   **ChEMBL**: Bioactivity database for drug-like molecules.
-   **PubChem**: Biological activities of small molecules.
-   **DrugBank**: Detailed drug and drug target data.
-   **BindingDB**: Binding affinities of protein-ligand complexes.
-   **ZINC20**: Commercially available compounds for virtual screening.
-   **PDB (RCSB)**: 3D structures of proteins and nucleic acids.

### 9. Literature & Text Mining
*Scientific publications and textual evidence.*
-   **PubMed / Europe PMC**: Biomedical literature search.
-   **Crossref**: Digital Object Identifier (DOI) registration agency.
-   **bioRxiv / medRxiv**: Preprints for biology and medicine.
-   **Semantic Scholar**: AI-driven research paper search.

### 10. Plant & Microbiome Omics
*Specialized domains for natural products and microbiome interactions.*
-   **MGnify**: Microbiome data analysis.
-   **HMP**: Human Microbiome Project.
-   **Planteome**: Plant reference ontologies.
-   **Phytozome**: Plant comparative genomics.

---

## Review & Improvements

The original workflow has been enhanced with the following "State-of-the-Art" additions:

1.  **Generative AI Integration**: Added specific references to Diffusion Models (DiffDock, RFdiffusion) which represent the current SOTA over older generative methods.
2.  **Structural Biology Revolution**: Explicit inclusion of **AlphaFold 3** and **ESMFold** for predicting structures of complexes (protein-protein, protein-ligand), reducing reliance on crystallography alone.
3.  **Experimental Validation Steps**: Added critical "Wet Lab" validation steps (Target Validation, Hit Confirmation) which were implicit or minimized. AI predicts, but biology validates.
4.  **Feedback Loops**: Emphasized the "Design-Make-Test-Analyze" cycle where experimental data retrains the AI models (Active Learning).
5.  **Comprehensive Omics**: Expanded descriptions for Cheminformatics and specialized omics to provide clear definitions of their utility in the pipeline.
